Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
57%
Relapsed or Refractory multiple Myeloma
41%
Acute Myeloid Leukemia
28%
Carfilzomib
23%
Lenalidomide
22%
Overall Survival
20%
Myelodysplastic Syndrome
19%
Bortezomib
17%
Graft-versus-host Disease (GvHD)
17%
Phase II Study
17%
Myeloma
15%
Protease Inhibitors
15%
Granulocyte Colony-stimulating Factor (G-CSF)
15%
Unrelated Donor
13%
Confidence Interval
12%
Multiple Myeloma Patients
12%
Progression-free Survival
11%
Overall Response Rate
11%
Autologous Transplantation
10%
Myeloma Cells
10%
Reduced-intensity Conditioning
10%
Leukemia
10%
Transplantation
9%
Chronic Myeloid Leukemia
8%
Hematopoietic Cell Transplantation
8%
Allogeneic Transplantation
8%
Complete Remission
8%
Marrow Transplantation
7%
Non-Hodgkin Lymphoma
7%
Hazard Ratio
7%
Relapsed or Refractory
7%
Peripheral Blood
7%
Allogeneic Peripheral Blood Stem Cell Transplantation
7%
Chemotherapy
7%
Older Patients
7%
Azacitidine
7%
Total Body Irradiation
7%
Phase II Trial
7%
Adverse Events
6%
Leukemia Patients
6%
Pretransplant
6%
Bone Marrow
6%
High Risk
6%
Older Adults
6%
Cyclophosphamide
6%
Maintenance Therapy
6%
Pomalidomide
6%
Cytarabine
6%
Neutropenia
5%
Medicine and Dentistry
Multiple Myeloma
93%
Hematopoietic Cell
25%
Acute Myeloid Leukemia
23%
Overall Survival
22%
Transplantation
21%
Carfilzomib
21%
Cell Transplantation
20%
Disease
15%
Myeloma
15%
Myelodysplastic Syndrome
15%
Lenalidomide
15%
Malignant Neoplasm
12%
Bortezomib
12%
Proteasome Inhibitor
11%
Progression Free Survival
10%
Allograft
10%
Stem Cell Transplant
9%
Adverse Event
9%
Autologous Stem Cell Transplantation
9%
Chemotherapy
9%
Dexamethasone
9%
Leukemia
9%
Granulocyte Colony Stimulating Factor
8%
Reduced Intensity Conditioning
8%
Hazard Ratio
7%
Graft Versus Host Reaction
7%
Chronic Myelogenous Leukemia
7%
Autotransplantation
7%
Low Drug Dose
6%
Arm
6%
Azacitidine
6%
Myeloma Cell
5%
Conditioning
5%
Acute Lymphoblastic Leukemia
5%
Drug Resistance
5%
Whole Body Radiation
5%
Cyclophosphamide
5%
Allogeneic Peripheral Blood Stem Cell Transplantation
5%
Neoplasm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
81%
Acute Myeloid Leukemia
21%
Lenalidomide
20%
Dexamethasone
17%
Myelodysplastic Syndrome
16%
Overall Survival
15%
Bortezomib
15%
Disease
15%
Myeloma
13%
Remission
11%
Malignant Neoplasm
11%
Adverse Event
10%
Carfilzomib
9%
Progression Free Survival
8%
Proteasome Inhibitor
8%
Cyclophosphamide
7%
Azacitidine
7%
Pharmacokinetics
7%
Granulocyte Colony Stimulating Factor
6%
Graft Versus Host Reaction
6%
Cytarabine
5%
Chemotherapy
5%
Drug Resistance
5%
Elotuzumab
5%
Plerixafor
5%